期刊
CELL RESEARCH
卷 23, 期 1, 页码 33-48出版社
INST BIOCHEMISTRY & CELL BIOLOGY
DOI: 10.1038/cr.2013.1
关键词
reprogramming; direct fate conversion; directed differentiation
类别
资金
- NIH (Progenitor Cell Biology Consortium) [UO1-HL100001, RC4-DK090913, R24DK092760]
- Ellison Medical Foundation
- Doris Duke Medical Foundation
- Harvard Stem Cell Institute
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100001] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK092760, RC4DK090913] Funding Source: NIH RePORTER
Human diseases such as heart failure, diabetes, neurodegenerative disorders, and many others result from the deficiency or dysfunction of critical cell types. Strategies for therapeutic tissue repair or regeneration require the in vitro manufacture of clinically relevant quantities of defined cell types. In addition to transplantation therapy, the generation of otherwise inaccessible cells also permits disease modeling, toxicology testing and drug discovery in vitro. In this review, we discuss current strategies to manipulate the identity of abundant and accessible cells by differentiation from an induced pluripotent state or direct conversion between differentiated states. We contrast these approaches with recent advances employing partial reprogramming to facilitate lineage switching, and discuss the mechanisms underlying the engineering of cell fate. Finally, we address the current limitations of the field and how the resulting cell types can be assessed to ensure the production of medically relevant populations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据